文献速递头颈外科咽喉与嗓音

T4期喉癌及下咽癌放化疗保器官治疗的结局

Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer.
PubMed 文献 · Laryngoscope · 2022-07-08

本研究回顾了1997年至2015年T4期喉癌(44例)和下咽癌(53例)非手术治疗,分析长期疗效和功能结局。喉癌2年/5年总生存率为73%/38%,下咽癌为52%/29%;喉癌局部区域失败率25%,下咽癌19%。结论认为本组结局优于既往报道。

要点

  • 喉癌2年/5年总生存率为73%/38%,下咽癌为52%/29%。
  • 喉癌局部区域失败率25%,下咽癌19%。
  • 喉癌68%和下咽癌85%接受经皮内镜下胃造瘘管,32%和40%接受气管套管。

核心结论

  • 对于不可切除或拒绝手术的T4期喉癌和下咽癌患者,本研究报告的结局优于既往报道。

研究设计与样本

  • 回顾性分析1997年至2015年T4期喉癌(n=44)和下咽癌(n=53)非手术治疗,进行单变量分析。

主要发现

  • 喉癌患者2年/5年总生存率分别为73%/38%,下咽癌患者分别为52%/29%。
  • 喉癌局部区域失败率为25%,下咽癌为19%。
  • 喉癌单变量分析中,N3淋巴结状态和非调强放疗与总生存负相关;单纯放疗影响无病生存;年龄>70岁与局部区域失败相关。
  • 下咽癌单变量分析中,仅T4b状态显著影响总生存。
  • 喉癌68%和下咽癌85%接受经皮内镜下胃造瘘管,喉癌32%和下咽癌40%接受气管套管;末次随访时,喉癌66%和下咽癌40%既无气管套管也无胃造瘘管。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Limited data is available to guide non-surgical management of Stage T4 larynx and hypopharynx cancer patients who have inoperable disease or refuse surgery. We aim to review the nonoperative management of T4 laryngeal and hypopharyngeal cancer and report the long-term therapeutic and functional outcomes. METHODS: We reviewed the nonoperative management of T4 laryngeal (n = 44) and hypopharyngeal (n = 53) cancer from 1997 to 2015 and performed a univariate analysis (UVA). RESULTS: The 2-/5-year OS rates were 73%/38% for larynx patients and 52%/29% for hypopharynx patients. Locoregional failure (LRF) occurred in 25% and 19% of larynx and hypopharynx patients, respectively. On UVA of the larynx subset, N3 nodal status and non-intensity-modulated radiation therapy were negatively associated with OS; treatment with radiation therapy alone impacted disease-free survival; and age >70 was associated with LRF. On UVA of the hypopharynx subset, only T4b status significantly impacted OS. In the larynx and hypopharynx groups, 68% and 85% received a percutaneous endoscopic gastrostomy (PEG) tube and 32% and 40% received a tracheostomy tube, respectively. At the last follow-up visit, 66% of our larynx cohort had neither tracheostomy or PEG placed and 40% of our hypopharynx cohort had neither. CONCLUSION: We report better than previously noted outcomes among T4 larynx and hypopharynx patients who have unresectable disease or refuse surgery. LEVEL OF EVIDENCE: 4 Laryngoscope, 133:1138-1145, 2023.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Eita A, Mohamed N, Rybkin A, et al. Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer. Laryngoscope. 2022. PMID: 35801573. doi:10.1002/lary.30279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。